每经记者｜杨建 每经编辑｜彭水萍 3、12月13日，据媒体报道，据中国神经科学学会脑机接口与交互分会年会透露，上海脑虎科技研发的 一款内置电池全植入脑机接口产品已于近期在复旦大学附属华山医院完成首例患者植入。据了解，目前 全球范围内掌握并验证内置电池全植入方案的公司数量极少，脑虎科技是除科技富豪马斯克的脑机接口 公司Neuralink之外，提供此类设备的首家中国公司，不仅填补了国内相关领域技术空白，也标志着中国 脑机接口技术跻身全球顶尖行列。复旦大学附属华山医院院长毛颖教授介绍称，患者术后1天即转入普 通病房，术后5天首次开机便成功实现意念操控。 点评：脑机接口下游应用市场潜力大，全球脑机接口医疗应用市场规模有望在2030年达到400亿美元， 2040年达到1450亿美元。脑机接口技术在医疗健康领域展现巨大潜力，为庞大的神经系统疾病患者群体 带来了新的治疗希望和康复途径。尤其是针对肢体运动障碍、意识与认知障碍、癫痫和精神性疾病等的 治疗和康复，脑机接口技术取得重要突破和长足进展。概念股包括中科信息、冠昊生物、爱朋医疗等。 （三）避雷针 （一）重要市场新闻 12月13日，据新华社报道，在中国国际经济交流中心举办 ...

（编辑 王江浩） 证券日报网讯 12月14日晚间，敏芯股份发布公告称，公司董事、副总经理、核心技术人员梅嘉欣先生 拟于2026年1月8日至2026年4月7日期间，通过集中竞价或大宗交易方式减持不超过220000股，即不超过 公司总股本的0.3925%，减持股份来源于IPO前取得及限制性股票归属。 ...

Corporate Changes - Wang Ying, the chairman of Pudong Jinqiao, has resigned due to work transfer [2] - Xu Yinghui has become the new actual controller of Gu Ao Technology after a voting rights entrustment agreement [4][5] Profit Distribution - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares for the first three quarters of 2025 [3] Investment Projects - Jiaze New Energy intends to invest approximately 3.557 billion yuan in a green hydrogen and methanol co-production project in Jixi City, Heilongjiang Province [6] - Longfei Optical Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [11] Financing Activities - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [7] Acquisitions - Zoli Pharmaceutical has signed an agreement to acquire a multi-trace element injection asset group from Future Medicine for a total price of 356 million yuan [8] Product Approvals - Nine安 Medical's U.S. subsidiary has received pre-market notifications from the FDA for its multi-detection kits for various viruses [9] National Projects - Saiyi Information has been approved to lead a national major science and technology project focused on intelligent manufacturing systems and robotics [10]

Group 1 - Pudong Jinqiao's chairman Wang Ying has resigned due to job transfer, ceasing to hold positions as director, chairman, and committee member [2] - Xiangsheng Medical plans to distribute a cash dividend of 3 yuan per 10 shares to all shareholders based on the total share capital [3] - Gu Ao Technology's actual controller has changed to Xu Yinghui, with stock resuming trading on December 15 [4] Group 2 - Jiaze New Energy plans to invest approximately 3.557 billion yuan in a green hydrogen and aviation fuel chemical co-production project in Jixi City [5] - Jinpan Technology has received approval from the China Securities Regulatory Commission to issue convertible bonds to unspecified investors [6] - Zoli Pharmaceutical intends to acquire a multi-trace element injection asset group for a total price of 356 million yuan [7] Group 3 - Jiuan Medical's U.S. subsidiary has received pre-market notifications from the FDA for four and three-in-one testing products [8] - Saiyi Information has been approved for a national major science and technology project focusing on intelligent manufacturing systems and robotics [9] - Changfei Fiber's subsidiary plans to participate in establishing an investment fund with a total subscription amount of 830 million yuan [10] Group 4 - Chengfeng Technology's shareholder, Hangzhou Hongwo, plans to reduce its stake by up to 3% of the company's shares [12] - Minxin Co., Ltd.'s deputy general manager plans to reduce holdings by up to 220,000 shares, representing 0.3925% of the total share capital [13] - Xinle Energy's director plans to reduce holdings by up to 400,000 shares, accounting for 0.07% of the total share capital [14]

格隆汇12月14日丨敏芯股份(688286.SH)发布公告，因个人资金需求，公司董事、副总经理、核心技术 人员梅嘉欣拟通过集中竞价、大宗交易的方式减持公司股份数量合计不超过22万股，即不超过公司总股 本的0.3925%。自本公告披露之日起15个交易日后的3个月内进行(窗口期不减持，中国证监会、上海证 券交易所相关法律法规、规范性文件规定不得进行减持的其他时间不减持)。 ...

人民财讯12月14日电，敏芯股份(688286)12月14日公告，持股2.98%的董事、副总经理、核心技术人员 梅嘉欣拟通过集中竞价、大宗交易的方式减持公司股份数量合计不超过22万股，即不超过公司总股本的 0.3925%。 ...

敏芯股份12月14日公告，公司董事、副总经理、核心技术人员梅嘉欣因个人资金需求，计划自2026年1 月8日起至2026年4月7日止，通过集中竞价和大宗交易方式减持公司股份不超过22万股，即不超过公司 总股本的0.3925%。减持价格将根据市场价格确定。本次减持计划实施具有不确定性。 ...

截至发稿，敏芯股份市值为44亿元。 每经头条（nbdtoutiao）——美股AI突变！OpenAI沦为"股价毒药"，硅谷八巨头一夜蒸发3.8万亿元市 值，专家：看好谷歌，其拥有两项致胜"法宝" 每经AI快讯，敏芯股份（SH 688286，收盘价：78.55元）12月14日晚间发布公告称，本次减持计划实施 前，苏州敏芯微电子技术股份有限公司董事、副总经理、核心技术人员梅嘉欣先生直接持有公司股份约 167万股，占公司总股本比例为2.98%，相关股份中约166万股为公司首次公开发行前取得的股份，并已 于2023年8月10日解除限售并上市流通，约1.15万股为公司2020年限制性股票激励计划归属所取得的股 份，并已于2021年12月3日起上市流通。因个人资金需求，梅嘉欣先生拟通过集中竞价、大宗交易的方 式减持公司股份数量合计不超过22万股，即不超过公司总股本的0.3925%。自本公告披露之日起15个交 易日后的3个月内进行。若在减持计划实施期间公司发生派息、送股、资本公积转增股本、配股等除权 除息事项，将根据股本变动对减持数量进行相应调整。 2024年1至12月份，敏芯股份的营业收入构成为：集成电路占比99.16%， ...

证券代码：688286 证券简称：敏芯股份 公告编号：2025-066 苏州敏芯微电子技术股份有限公司 董事兼高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： | | | 一、减持主体的基本情况 1 董事持有的基本情况 本次减持计划实施前，苏州敏芯微电子技术股份有限公司（以下简称"公 司"） 董事、副总经理、核心技术人员梅嘉欣先生直接持有公司股份 1,670,430 股，占公司总股本比例为 2.98%，上述股份中 1,658,930 股为公司首次公开发行 前取得的股份，并已于 2023 年 8 月 10 日解除限售并上市流通，11,500 股为公司 2020 年限制性股票激励计划归属所取得的股份，并已于 2021 年 12 月 3 日起上 市流通。 减持计划的主要内容 因个人资金需求，梅嘉欣先生拟通过集中竞价、大宗交易的方式减持公司股 份数量合计不超过 220,000 股，即不超过公司总股本的 0.3925%。自本公告披露 之日起 15 个交易日后的 3 个月内进行（ ...

Core Insights - The focus of AI development is shifting towards terminal applications, with companies like Li Auto, Alibaba, and ByteDance launching AI glasses, indicating a competitive landscape for the next generation of interactive devices [1][2] - The AI end-side market is expected to grow significantly, with predictions that by 2027, over 70% of new intelligent terminals and applications will be widely adopted in key sectors [2] - The integration of AI models with hardware is seen as a crucial path for commercialization, as hardware provides a clear monetization channel for AI capabilities [3][4] Group 1: Industry Dynamics - Major tech companies are accelerating their investments in AI end-side applications, with notable collaborations such as OpenAI partnering with Foxconn for next-gen AI infrastructure [2] - The AI end-side market is projected to be one of the fastest-growing tech sectors globally, with a potential market size increase from hundreds of billions to trillions [2] - AI glasses are viewed as revolutionary devices that can capture over 80% of human sensory input, marking a significant shift in human-computer interaction [2] Group 2: Supply Chain and Innovation - The AI hardware sector is heavily reliant on the mature supply chain of consumer electronics, with companies like Alibaba forming alliances to create an ecosystem for AI glasses [6][7] - There is a growing demand for components such as sensors and processors, leading to increased orders for companies involved in the AI supply chain [6][7] - New technologies like bone conduction and optical waveguides are emerging as opportunities within the AI hardware space, with companies actively developing innovative products [7] Group 3: Challenges and Considerations - The AI end-side industry faces challenges such as matching market demand, overcoming manufacturing bottlenecks, and building user trust [8] - The quest for a "killer application" remains a pressing question, with the need for improved ecosystem support and further advancements in AI technology [8] - Ethical considerations, data security, and privacy protection are critical issues that need to be addressed for the long-term development of the AI industry [8]